Astra works to avoid a datopotamab double dip
As Tropion-Breast01 is toplined positive Astra ensures the markets know that overall survival isn’t a washout.
Novartis goes 0 for 2 in PD-1 blockade
BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.
12 years on, Jakafi faces serious JAK competition
Momelotinib gains full US approval in a broader setting than expected, validating GSK’s $1.9bn buyout of Sierra Oncology.
Bristol seeks novelty in TIGIT
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
AbbVie opt-out puts the focus on TeneoOne
The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.
